- Home
- FRBA vs AUTL Comparison
FRBA vs AUTL Comparison
Compare FRBA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 407.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | FRBA | AUTL |
|---|---|---|
| Price | $15.20 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.00 | $8.50 |
| AVG Volume (30 Days) | 46.0K | ★ 1.4M |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $14.68 | $80.32 |
| Revenue Next Year | $6.08 | $53.96 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $14.21 | $1.15 |
| 52 Week High | $18.11 | $2.70 |
Technical Indicators
Market Signals| Indicator | FRBA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 44.88 |
| Support Level | $14.76 | $1.32 |
| Resistance Level | $16.11 | $1.52 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 0.00 | 8.47 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.